Applications of pox virus vectors to vaccination: an update. - Wikidata - wikimedia - TriplyDB

Applications of pox virus vectors to vaccination: an update.

Applications of pox virus vectors to vaccination: an update.

http://www.wikidata.org/entity/Q34403246

about

The genome of canarypox virus A phase I trial of pox PSA vaccines (PROSTVAC-VF) with B7-1, ICAM-1, and LFA-3 co-stimulatory molecules (TRICOM) in patients with prostate cancer Deletion of the vaccinia virus gene A46R, encoding for an inhibitor of TLR signalling, is an effective approach to enhance the immunogenicity in mice of the HIV/AIDS vaccine candidate NYVAC-C Highly efficient induction of protective immunity by a vaccinia virus vector defective in late gene expression Current Status of Veterinary Vaccines Evidence-Based Biosafety: a Review of the Principles and Effectiveness of Microbiological Containment Measures Current progress in the development of therapeutic vaccines for chronic hepatitis B virus infection Overcoming immunity to a viral vaccine by DNA priming before vector boosting Avipoxviruses: infection biology and their use as vaccine vectors Modulation of NKp30- and NKp46-mediated natural killer cell responses by poxviral hemagglutinin Improved innate and adaptive immunostimulation by genetically modified HIV-1 protein expressing NYVAC vectors Improved NYVAC-based vaccine vectors Protection of chickens against avian influenza with non-replicating adenovirus-vectored vaccine Human immunodeficiency virus vaccine trials Vaxvec: The first web-based recombinant vaccine vector database and its data analysis Immunogenicity of fowlpox virus expressing the avian influenza virus H5 gene (TROVAC AIV-H5) in cats.Characterization of host responses against a recombinant fowlpox virus-vectored vaccine expressing the hemagglutinin antigen of an avian influenza virus.Induction of CD8+ T cells using heterologous prime-boost immunisation strategies.Approaches to improve engineered vaccines for human immunodeficiency virus and other viruses that cause chronic infections.Mucosal immunity and tolerance: relevance to vaccine development.Role of genes that modulate host immune responses in the immunogenicity and pathogenicity of vaccinia virus.Inactivation of human immunodeficiency virus type 1 infectivity with preservation of conformational and functional integrity of virion surface proteins.Immunization with a modified vaccinia virus expressing simian immunodeficiency virus (SIV) Gag-Pol primes for an anamnestic Gag-specific cytotoxic T-lymphocyte response and is associated with reduction of viremia after SIV challenge Comparative efficacy of recombinant modified vaccinia virus Ankara expressing simian immunodeficiency virus (SIV) Gag-Pol and/or Env in macaques challenged with pathogenic SIV Mature dendritic cells infected with canarypox virus elicit strong anti-human immunodeficiency virus CD8+ and CD4+ T-cell responses from chronically infected individuals.Type I interferons mediate the innate cytokine response to recombinant fowlpox virus but not the induction of plasmacytoid dendritic cell-dependent adaptive immunity.Virus-vectored influenza virus vaccines.A novel high-throughput vaccinia virus neutralization assay and preexisting immunity in populations from different geographic regions in China Herpes simplex virus vectors elicit durable immune responses in the presence of preexisting host immunity.The efficacy of genetic vaccination is dependent upon the nature of the vector system and antigen.The ethical dimensions of wildlife disease management in an evolutionary context.New hope for an AIDS vaccine.Cellular and biochemical differences between two attenuated poxvirus vaccine candidates (MVA and NYVAC) and role of the C7L gene.Deletion of C7L and K1L genes leads to significantly decreased virulence of recombinant vaccinia virus TianTan Virological and immunological characterization of novel NYVAC-based HIV/AIDS vaccine candidates expressing clade C trimeric soluble gp140(ZM96) and Gag(ZM96)-Pol-Nef(CN54) as virus-like particles.Mucosal vaccination overcomes the barrier to recombinant vaccinia immunization caused by preexisting poxvirus immunity.Vaccine-induced immunity in baboons by using DNA and replication-incompetent adenovirus type 5 vectors expressing a human immunodeficiency virus type 1 gag gene.A national multicenter phase 2 study of prostate-specific antigen (PSA) pox virus vaccine with sequential androgen ablation therapy in patients with PSA progression: ECOG 9802.Vaccinia virus infection of mature dendritic cells results in activation of virus-specific naïve CD8+ T cells: a potential mechanism for direct presentation.Vaccinia as a vector for gene delivery.

P2860

Q24630284-B68E1FEA-B45B-4FBB-B9F5-0FF99C0915DC Q25255692-C7AC39CA-FB92-4D50-A1E3-073820D8097B Q27306437-15FF6650-171C-4294-A599-32ADECDEB0A1 Q27469703-9D9F626D-74B3-462E-B3FA-81BA988960A8 Q27480923-A06E7327-6887-43EB-A689-E12EF7E33263 Q27486575-22322792-65BB-4B48-B0C0-C9B2B5205296 Q28076279-C32B9F46-3834-4615-8C6E-68156C5E3A67 Q28217213-F6FF1A1D-69D6-498B-A00E-5258D6B2C036 Q28304570-9EA5D964-D962-4449-AE2A-84ED99F26DCE Q28476707-BDBC0731-B358-4C3B-8E83-1C5CF5D35FB0 Q28742751-B013B173-DD78-4979-9340-D2CFE183AC08 Q28742982-4AF5D179-F43F-465E-89B0-825D0C046884 Q30368615-06402790-B6D7-45EB-9086-A03D972FD1D6 Q30424366-EBDAD72F-5426-42AE-995E-3179BE452900 Q30996881-938554A9-A6C7-4C73-8EA6-8629773FFA96 Q33226785-60524F17-FB78-441E-9E1D-68E33066E69D Q33725157-2741D099-865A-4CCF-89F6-03CF6ABC7AB3 Q33776098-FE194F35-C107-4D1A-9A5A-DD6EE2A9373A Q33776155-3A1CC6C0-4488-43DD-9911-742E92636404 Q33776172-912B17D3-3DE0-440D-8599-E0C28F8DDDF6 Q33780579-C1639CF8-C645-41EB-853D-ED15E61800E5 Q33784777-028AF243-2495-4FD4-8596-6B69D4D368B2 Q33799497-A59DB715-1102-458D-92E5-27C778FABFAC Q33800033-450B67FC-C7AD-4354-8DE3-46F1BC3DDE18 Q33850510-C81B1BC2-3CDD-4B95-B276-3DBFDDA5A3BA Q33990693-D9ED5323-EF47-44A9-968D-9202EBF3CE8B Q34102268-787FDE6E-694D-44E4-95C5-6C63F4FF5989 Q34206208-B14D8312-1172-4EFF-8223-3A46DF0019A2 Q34335296-F46834E9-1631-4B94-B2BD-766584CD2A76 Q34482074-D0F9F508-14CE-4959-8531-EA7C54D0C0CF Q34490086-DAE5DFB8-7E42-48C0-95A1-AD6BDB11D9AB Q34632063-B5C6B0FB-6178-4AA0-AB60-CC0390712B7F Q34651266-899784AB-D5B3-40BE-890B-44F810CB22FE Q34809121-29644CAA-9231-4117-A1D5-0D8BAEA2CB5B Q34991112-DFD9D79F-6F9A-4180-A90D-985148C421E7 Q35130248-34CBF8F3-1AAD-43B6-B534-D1CC2F90ED78 Q35150143-E2F1D9EF-7FC5-42BC-BD67-8526CB8AC832 Q35756538-DAFE58B7-4EBF-480E-BC8D-00C404716E7A Q35774599-89F5A4B6-3161-4D6B-BE3E-F592847F3684 Q35790868-B684D7D3-5194-429C-ACF1-E8C7D5022B80

P2860

Applications of pox virus vectors to vaccination: an update.

http://www.wikidata.org/entity/Q34403246

description

1996 nî lūn-bûn

@nan

1996 թուականի Հոկտեմբերին հրատարակուած գիտական յօդուած

@hyw

1996 թվականի հոտեմբերին հրատարակված գիտական հոդված

@hy

1996年の論文

@ja

1996年論文

@yue

1996年論文

@zh-hant

1996年論文

@zh-hk

1996年論文

@zh-mo

1996年論文

@zh-tw

1996年论文

@wuu

name

Applications of pox virus vectors to vaccination: an update.

@ast

Applications of pox virus vectors to vaccination: an update.

@en

Applications of pox virus vectors to vaccination: an update.

@nl

type

label

Applications of pox virus vectors to vaccination: an update.

@ast

Applications of pox virus vectors to vaccination: an update.

@en

Applications of pox virus vectors to vaccination: an update.

@nl

prefLabel

Applications of pox virus vectors to vaccination: an update.

@ast

Applications of pox virus vectors to vaccination: an update.

@en

Applications of pox virus vectors to vaccination: an update.

@nl

P1433

Q34403246-837736B9-3EB9-4CFE-950E-3266A199C4D9

P1476

Q34403246-390144EF-473C-43D0-A4AE-2D0647811896

P2093

Q34403246-B0737C5E-B630-4BAE-9EAC-8C5BB4DE5F0B

P2860

Q34403246-1A279626-9151-43B2-AE18-C884A3327E57

Q34403246-240A9482-5BAC-4396-B1F2-C53333BD3510

Q34403246-2D8BF68B-BF2A-4F86-A336-21F461406D42

Q34403246-32CE4A74-F7DB-4A3D-8D94-64D65DC3E7DA

Q34403246-33714545-2E35-48E3-A077-8262F7CD0323

Q34403246-49C74624-1872-47C4-A129-F49678DD0B1C

Q34403246-526C47B2-6728-43A6-97D2-892B6905E9E4

Q34403246-5CFC7CB4-16FC-4EAA-B979-E2FE3AA0716B

Q34403246-7F76C106-745F-427E-9EAD-8705D77CC038

Q34403246-8723037E-9A89-4F23-9EDE-FF01C5588479

P304

Q34403246-476745C9-39BD-45B5-B376-353C2956D2D2

P31

Q34403246-7F1795F7-3410-451C-BB29-F6E6209919DA

P356

Q34403246-AA8966DD-BDD8-44B1-915E-857B223A6D17

P407

Q34403246-E938D580-3DD3-4FFA-B886-48EFD8D8D21C

P433

Q34403246-88CF2470-9C35-47CD-BDE0-22BCAE5DDCFA

P478

Q34403246-9EA4B8DA-577F-43CD-813A-8802397C35FC

P577

Q34403246-2E45A137-5A2C-445C-9BDE-519A0C80283C

P5875

Q34403246-68A8AF28-B660-4AD4-81D7-0843975DFFFE

P698

Q34403246-DC26E6D4-6004-4445-AF48-42F76DD8F893

P921

Q34403246-E9ED415B-A89E-4BCE-8FD0-7D1C96EB1791

P932

Q34403246-2F9ADBCB-BA37-456C-9D04-B9C90A85B76F

P356

PNAS.93.21.11349

P1433

Proceedings of the National Academy of Sciences of the United States of America

P1476

Applications of pox virus vectors to vaccination: an update.

@en

P2093

Paoletti E

http://www.w3.org/2001/XMLSchema#string

P2860

Human safety and immunogenicity of a canarypox-rabies glycoprotein recombinant vaccine: an alternative poxvirus vector system

Construction of poxviruses as cloning vectors: insertion of the thymidine kinase gene from herpes simplex virus into the DNA of infectious vaccinia virus

Vaccinia virus: a selectable eukaryotic cloning and expression vector.

p53 as a target for cancer vaccines: recombinant canarypox virus vectors expressing p53 protect mice against lethal tumor cell challenge.

Attenuated vaccinia virus-circumsporozoite protein recombinants confer protection against rodent malaria.

Protection of cats against feline leukemia virus by vaccination with a canarypox virus recombinant, ALVAC-FL.

Poxvirus-based vaccine candidates for cancer, AIDS, and other infectious diseases.

Vaccination of pigs against pseudorabies with highly attenuated vaccinia (NYVAC) recombinant viruses.

NYVAC: a highly attenuated strain of vaccinia virus.

Induction of cytotoxic T lymphocytes by recombinant canarypox (ALVAC) and attenuated vaccinia (NYVAC) viruses expressing the HIV-1 envelope glycoprotein.

P304

11349-11353

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1073/PNAS.93.21.11349

http://www.w3.org/2001/XMLSchema#string

P407

P433

21

http://www.w3.org/2001/XMLSchema#string

P478

93

http://www.w3.org/2001/XMLSchema#string

P577

1996-10-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

14331033

http://www.w3.org/2001/XMLSchema#string

P698

8876138

http://www.w3.org/2001/XMLSchema#string

P921

vector-borne disease

P932

38060

http://www.w3.org/2001/XMLSchema#string